Presentation is loading. Please wait.

Presentation is loading. Please wait.

Figure 2 The K19del mutation affects the expression and solubility of CHP1 The K19del mutation affects the expression and solubility of CHP1 (A) Western.

Published byAlexander McBride Modified over 5 years ago

Similar presentations

Presentation on theme: "Figure 2 The K19del mutation affects the expression and solubility of CHP1 The K19del mutation affects the expression and solubility of CHP1 (A) Western."— Presentation transcript:

1 Figure 2 The K19del mutation affects the expression and solubility of CHP1
The K19del mutation affects the expression and solubility of CHP1 (A) Western blot (WB) from HEK293T lysates transiently expressing CHP1-WT-V5, CHP1-K19del-V5, or empty V5-vector (control) collected 24, 48, and 72 hours after transfection. Protein lysates were probed with antibodies against V5 to detect CHP1-WT and mutant proteins, and GAPDH as loading control. Expression of CHP1-K19del-V5 is almost undetectable after 72 hours. The graph represents quantification of CHP1 relative expression over different time points. Bars show the mean ± SEM. (B) Determination of CHP1-WT-V5 and K19del-V5 transcripts by semiquantitative RT-PCR. The graph represents quantification of CHP1-V5 transcripts normalized to HPRT expression. Bars show the mean ± SEM. Negligible differences were observed between WT and CHP1-K19del transcripts. (C) Subcellular fractionation of protein lysates from HEK293T transiently overexpressing CHP1-WT-V5 or CHP1-K19del-V5 48 hours after transfection. Lysates were separated into soluble (cytoplasmic) and insoluble (cytoskeletal) fractions by differential lysis and centrifugation. Representative WB from total lysates and fractions were probed with V5 antibodies to detect CHP1-WT and mutant proteins. HSP90 and Vimentin were used as enrichment markers for soluble and insoluble fractions, respectively. Graphs represent quantification of relative expression of CHP1 in the soluble and insoluble fractions. Bars show the mean ± SEM from 3 independent blots. “*” denotes statistical significance (p ≤ 0.05 two-tailed Student t test) between CHP1-WT and CHP1-K19del expression. GAPDH = glyceraldehyde 3-phosphate dehydrogenase; HPRT = hypoxanthine-guanine phosphoribosyltransferase; WT = wild type. Natalia Mendoza-Ferreira et al. Neurol Genet 2018;4:e209 Copyright © 2018 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology

Download ppt "Figure 2 The K19del mutation affects the expression and solubility of CHP1 The K19del mutation affects the expression and solubility of CHP1 (A) Western."

Similar presentations

Figure Pedigrees of the SCA42 families identified in this study

Figure Pedigrees of the SCA42 families identified in this study
Figure 4 K19del mutation alters CHP1 association into functional complexes, impairs NHE1 membrane targeting, and potentially compromises protein conformational.

Figure 4 K19del mutation alters CHP1 association into functional complexes, impairs NHE1 membrane targeting, and potentially compromises protein conformational.
Figure 1 Phenotype and genotype of an undiagnosed family with autosomal recessive spastic ataxia Phenotype and genotype of an undiagnosed family with autosomal.

Figure 1 Phenotype and genotype of an undiagnosed family with autosomal recessive spastic ataxia Phenotype and genotype of an undiagnosed family with autosomal.
Figure 2 Sanger sequencing, conservation, and summary of known ACO2 mutations Sanger sequencing, conservation, and summary of known ACO2 mutations (A)

Figure 2 Sanger sequencing, conservation, and summary of known ACO2 mutations Sanger sequencing, conservation, and summary of known ACO2 mutations (A)
Figure 1 Summary of prior diagnostic workup in neuromuscular disorder cases Summary of prior diagnostic workup in neuromuscular disorder cases Percentage.

Figure 1 Summary of prior diagnostic workup in neuromuscular disorder cases Summary of prior diagnostic workup in neuromuscular disorder cases Percentage.
Figure 3 Pedigree of familial idiopathic transverse myelitis

Figure 3 Pedigree of familial idiopathic transverse myelitis
Figure 1 Imaging, histopathology, and molecular evaluation of case 1 with definite leptomeningeal angiomatosis Imaging, histopathology, and molecular evaluation.

Figure 1 Imaging, histopathology, and molecular evaluation of case 1 with definite leptomeningeal angiomatosis Imaging, histopathology, and molecular evaluation.
Figure 1 Box plot of the venous diameter in lesions

Figure 1 Box plot of the venous diameter in lesions
Figure 1 Hierarchical clustering (HCL) outcome of all tested samples with the expression profile of the case report set as unknown Hierarchical clustering.

Figure 1 Hierarchical clustering (HCL) outcome of all tested samples with the expression profile of the case report set as unknown Hierarchical clustering.
Figure Sural nerve electron microscopy

Figure Sural nerve electron microscopy
Figure 5 Chp1 downregulation in zebrafish leads to CaP-MN, cerebellar, and movement defects rescued with WT, but not mutant CHP1 mRNA Chp1 downregulation.

Figure 5 Chp1 downregulation in zebrafish leads to CaP-MN, cerebellar, and movement defects rescued with WT, but not mutant CHP1 mRNA Chp1 downregulation.
Figure 2 Anti-LINGO-1 (Li81) does not affect cytokine production

Figure 2 Anti-LINGO-1 (Li81) does not affect cytokine production
Figure 1 Spine MRI, sagittal and axial views of patients with idiopathic transverse myelitis with VPS37A mutations Spine MRI, sagittal and axial views.

Figure 1 Spine MRI, sagittal and axial views of patients with idiopathic transverse myelitis with VPS37A mutations Spine MRI, sagittal and axial views.
Figure Pedigree of the family

Figure Pedigree of the family
Figure 3 Transcripts of the splicing mutation (c

Figure 3 Transcripts of the splicing mutation (c
Figure 3 Complete loss of neurofilament light (NEFL) protein in cultured patient neurons Complete loss of neurofilament light (NEFL) protein in cultured.

Figure 3 Complete loss of neurofilament light (NEFL) protein in cultured patient neurons Complete loss of neurofilament light (NEFL) protein in cultured.
Figure 2 Luciferase assays of transiently transfected HEK 293 cells with reporter constructs containing the 766-bp wild-type KCNJ18 or c.-542 T/A mutant.

Figure 2 Luciferase assays of transiently transfected HEK 293 cells with reporter constructs containing the 766-bp wild-type KCNJ18 or c.-542 T/A mutant.
Fig. 1. Muscles of LAMA2 MD patients and dyW/dyW mice contain high amounts of laminin-α4 and show deficits in BM. Muscles of LAMA2 MD patients and dyW/dyW.

Fig. 1. Muscles of LAMA2 MD patients and dyW/dyW mice contain high amounts of laminin-α4 and show deficits in BM. Muscles of LAMA2 MD patients and dyW/dyW.
Figure 2 Correlation between total IgG levels and anti-AQP4 IgG titer

Figure 2 Correlation between total IgG levels and anti-AQP4 IgG titer
Figure 1 Dominant and recessive missense and nonsense variants in neurofilament light (NEFL)‏ Dominant and recessive missense and nonsense variants in.

Figure 1 Dominant and recessive missense and nonsense variants in neurofilament light (NEFL)‏ Dominant and recessive missense and nonsense variants in.

Similar presentations

Ads by Google